晚期非小细胞肺癌维持治疗的研究进展  

Maintenance therapy of advanced non-small-cell lung cancer

作　　者：沈玉萍[1] 张西[1] 许青[1] 

机构地区：[1]同济大学附属第十人民医院肿瘤科,上海200072

出　　处：《上海医药》2013年第23期15-18,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：维持治疗分为继续维持治疗和换药维持治疗。研究证实,培美曲塞是一种既可用于换药维持治疗、也可用于继续维持治疗的晚期非小细胞肺癌化疗药物。另外,酪氨酸激酶抑制剂亦是一类非常有效的维持治疗选择,其中吉非替尼和厄洛替尼已被有关指南推荐用作维持治疗药物,但目前只能用于换药维持治疗。Maintenance therapy can be usually divided into continuation-maintenance and switch-maintenance. It is confirmed that the pemetrexed could be used as both continuation-maintenance drugs and switch-maintenance drugs in the treatment of advanced non-small-cell lung cancer. Tyrosine kinase inhibitors is another effective maintenance drugs, in which gefitinib or erlotinib has been recommended as a maintenance therapy drug in some guideline, however either one can be only used for switch-maintenance now.

关 键 词：晚期非小细胞肺癌 维持治疗靶 向治疗 

分 类 号：R734.2[医药卫生—肿瘤]